Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of Calgary.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Canadian Intensive Care Foundation
Information provided by:
University of Calgary
ClinicalTrials.gov Identifier:
NCT00522496
First received: August 27, 2007
Last updated: February 20, 2009
Last verified: February 2009
  Purpose

The purpose of this study is to:

  1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
  2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
  3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Condition
Brain Injuries, Traumatic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

Resource links provided by NLM:


Further study details as provided by University of Calgary:

Estimated Enrollment: 8
Study Start Date: July 2007
Estimated Study Completion Date: August 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All patients referred to Foothills Medical Centre, the regional trauma centre for Southern Alberta

Criteria

Inclusion Criteria:

  • Patient is 18 years of age or older
  • Patient has GCS less than 9
  • Patient requires intracranial pressure monitoring
  • Patient life expectancy greater than 72 hours

Exclusion Criteria:

  • Patient's TBI is greater than 24 hours old
  • Patient is less than 18 years of age
  • Patient does not require intracranial pressure monitoring
  • Patient has life expectancy less than 72 hours
  • Patient has GCS greater or equal to 9
  • Patient is currently enrolled in another study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00522496

Contacts
Contact: David A Zygun, MD 403-944-1691 dzygun@ucalgary.ca

Locations
Canada, Alberta
Foothills Medical Centre Recruiting
Calgary, Alberta, Canada, T2N 2T9
Contact: David A Zygun, MD    403-944-1691    dzygun@ucalgary.ca   
Principal Investigator: David A Zygun, MD         
Sub-Investigator: John Hurlbert, MD         
Sub-Investigator: Ian Parney, MD         
Sub-Investigator: Walter Hader, MD         
Sub-Investigator: Clare Gallagher, MD         
Sub-Investigator: Wee Yong, P.hD         
Sub-Investigator: Christopher Doig, MD         
Sub-Investigator: Paul Kubes, MD         
Sub-Investigator: Andreas Kramer, MD         
Sponsors and Collaborators
University of Calgary
Canadian Intensive Care Foundation
Investigators
Principal Investigator: Zygun A David, MD University of Calgary
  More Information

No publications provided

Responsible Party: David Zygun Principal Investigator, University of Calgary
ClinicalTrials.gov Identifier: NCT00522496     History of Changes
Other Study ID Numbers: 20216
Study First Received: August 27, 2007
Last Updated: February 20, 2009
Health Authority: Canada: Ethics Review Committee

Keywords provided by University of Calgary:
Craniocerebral trauma
matrix metalloproteinase
microdialysis

Additional relevant MeSH terms:
Brain Injuries
Wounds and Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System

ClinicalTrials.gov processed this record on April 17, 2014